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nitrate-like action, has been used for treatment of unstable angina. In the present investigation,
we examined the effect of intravenous nicorandil on hemodynamics in patients with acute
decompensated heart failure (ADHF).
Methods: ADHF patients admitted to hospital with pulmonary artery wedge pressure
(PAWP)≥ 18mmHg were enrolled. Patients received nicorandil by an intravenous bolus injec-
tion of 0.2mg/kg/5min followed by continuous infusion at a rate of 0.05, 0.10, or 0.20mg/kg/h
for 6 h.
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Results: Nicorandil administration caused a signiﬁcant decrease in PAWP and increase in the
cardiac index (CI) that began immediately after the injection and were maintained during
the continuous infusion. After 6 h, nicorandil administration at 0.2mg/kg/5min followed by
0.20mg/kg/h resulted in a decrease in PAWP (26.5%, p < 0.01), an increase in CI (15.8%, p < 0.05),
and a decrease in total peripheral resistance (13.8%, p < 0.01) in a dose-dependent manner. Nico-
randil decreased blood pressure signiﬁcantly, without an excessive decrease or negative impact
even in patients with lower systolic blood pressure.
Conclusion: Intravenous administration of nicorandil, by bolus injection followed by continu-
ous infusion, improves PAWP and CI in ADHF patients immediately and continuously as a potent
vasodilator with combined preload and afterload reduction. These results demonstrate that
tive new medication for the treatment of ADHF.
ardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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lasting 6 h. The composition of the groups according to
dosage in the two studies used in the analysis is describednicorandil is a safe and effec
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cute heart failure is a clinical syndrome with a variety of
nderlying diseases, and the number of patients with acute
ecompensated heart failure (ADHF) is increasing rapidly.
owever, the pathophysiology of ADHF and its treatment
re still incompletely understood, and, therefore, optimal
reatment for this condition remains somewhat controver-
ial. Guidelines for the treatment of ADHF were published
y the Japanese Circulation Society in 2006 [1], by the
uropean Society of Cardiology (ESC) in 2008 [2], and by
he American Heart Association in 2009 [3], and practical
ecommendations for prehospital and early management of
atients with ADHF have also been released [4]. In those
uidelines and practical recommendations, vasodilators are
n general currently considered to be a cardinal form of
herapy. However, because both the underlying diseases and
ffects of different vasodilators are quite available, the
trategy for vasodilator therapy for ADHF has not yet become
ully established.
Nicorandil is a vasodilator that combines KATP channel
pening action and nitrate-like action [5] and has been
sed for the treatment of angina pectoris (tablet for-
ula) and unstable angina (injection formula). The KATP
hannel opening action of nicorandil exerts a vasodilating
ffect by hyperpolarizing vascular smooth muscle mem-
ranes, thereby inhibiting calcium inﬂux into cells [6].
itrate-like action mainly dilates venous vessels via guany-
ate cyclase activation. In ischemic heart disease, nicorandil
as been reported to improve coronary circulation by dilat-
ng coronary resistance vessels in addition to large coronary
rteries [7,8]. Nicorandil has also been reported to have a
yocardial protective effect from reperfusion injury fol-
owing percutaneous coronary interventional procedures
9—11].
In chronic congestive heart failure in patients with a
elatively stable hemodynamic condition, nicorandil has
een reported to improve hemodynamics by reducing the
reload and afterload and increasing cardiac output when
dministered orally [12,13], as a single intravenous injec-
ion [14], or as a continuous infusion [15,16]. However,
e are not aware of any report of the evaluation of
he effects of intravenous nicorandil on hemodynamics in
atients with ADHF. The purpose of the present investi-
ation was to establish the adequate clinical dosage of
b
o
l
0icorandil based upon efﬁcacy and safety in patients with
DHF.
aterials and methods
wo Phase 2 studies were conducted between March 1995
nd February 2000 in 26 medical institutions throughout
apan to support the application for approval of ADHF as
n additional indication for nicorandil. These studies were
pproved by the institutional review board of each partici-
ating medical institution and conducted in compliance with
he principles of the Declaration of Helsinki and Japanese
ood Clinical Practice (GCP). Voluntary written informed
onsent to participate in the study was obtained from all
tudy patients or from their legally acceptable representa-
ives.
atients
tudy subjects were patients with ADHF who met all of
he following inclusion criteria: (1) placement of a Swan-
anz catheter was possible throughout the study period; (2)
ge 20 years or older; (3) pulmonary artery wedge pressure
PAWP) or diastolic pulmonary artery pressure≥ 18mmHg;
nd (4) written informed consent provided by patient or rep-
esentative. Exclusion criteria were: (1) serious arrhythmia;
2) cardiogenic shock or severe hypotension with systolic
lood pressure (SBP) below 90mmHg; (3) contraindications
or nicorandil injection; and (4) considered inappropriate
s a participant by an investigator. Nicorandil (Sigmart®
njection, Chugai, Tokyo, Japan, 12mg or 48mg, lyophilized
njection containing 12mg or 48mg of nicorandil per vial)
as used as the study drug, which was dissolved in physio-
ogical saline or 5% glucose solution.
Each patient group in the two studies received an ini-
ial bolus injection of nicorandil followed by an infusionelow.
Early Phase 2 study: The study had a multicenter,
pen-label, group comparison design and included the fol-
owing ﬁve groups according to dosage: 0.2mg/kg/5min +
.05mg/kg/h, 0.2mg/kg/5min + 0.10mg/kg/h, 0.2mg/kg/
o
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5min + 0.15mg/kg/h, 0.2mg/kg/5min + 0.20mg/kg/h, and
0.2mg/kg/5min + 0.25mg/kg/h.
Late Phase 2 study: The study had a randomized,
double-blind, parallel-group design and included the fol-
lowing three groups according to dosage: 0.2mg/kg/5min +
0.05mg/kg/h, 0.2mg/kg/5min + 0.10mg/kg/h, and 0.2mg/
kg/5min + 0.20mg/kg/h. Subjects were assigned to the
treatment group by a controller according to key codes using
permuted block randomization with a block size of three
(three subjects per block).
Fig. 1 shows the distribution of the patients. For
the two studies, we obtained consent from a total
of 128 patients, 99 of which were included in the
analysis. Twenty-nine patients were excluded for the fol-
lowing reasons: use of study drug dosages that were not
included in this analysis (0.2mg/kg/5min + 0.15mg/kg/h or
0.2mg/kg/5min + 0.25mg/kg/h; all the excluded patients
were from the early Phase 2 study), violation of inclusion or
exclusion criteria or concomitant use of a prohibited drug.
Study procedures
Baseline hemodynamic parameters were measured and
treatment with nicorandil was initiated if these parame-
ters were stable for at least 15min. In both studies, a single
0.2mg/kg dose of nicorandil was intravenously administered
over a 5-min period, after which the designated dose for
that patient’s group was intravenously administered con-
tinuously for 6 h. Concomitant use of the following classes
of drugs that could affect evaluation of the efﬁcacy of
nicorandil was prohibited at least 3 h before and during con-
tinuous infusion of the study drug: vasodilators, diuretics,
inotropic agents (except for digitalis), sulfonylurea hypo-
glycemic agents, human atrial natriuretic peptide agents,
-blockers, antiarrhythmic agents, and morphine and other
such opioids. However, use of digitalis, intravenous ﬂuids,
and agents used for treatment for non-cardiovascular dis-
eases were permitted during the nicorandil administration
provided the dosage remained stable.
The following baseline characteristics were determined:
gender, age, height, body weight, and underlying disease.
Hemodynamic parameters measured were heart rate (HR),
SBP, and diastolic blood pressure (DBP). The following
parameters were measured using a Swan-Ganz catheter or
were calculated: PAWP, cardiac index (CI), stroke volume
index (SVI), mean right atrial pressure (RAP), and total
peripheral resistance (TPR). Each parameter was measured
before, at 15 and 30min, and at 1, 2, 4, and 6 h after the
start of nicorandil administration. Adverse events were also
monitored.
Statistical analysis
Patients in the two studies who received nicorandil as
a 0.2mg/kg/5min bolus injection followed by continuous
infusion of 0.05, 0.10, or 0.20mg/kg/h were included in
the analysis. Statistics are presented as mean± standard
deviation (SD) or mean± standard error (SE). The baseline
characteristics of each group were analyzed using the 2 test
or one-way analysis of variance (one-way ANOVA). Hemody-
namic parameters were analyzed by compiling the changes
c
T
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ver time for each dosage and performing one-way repeated
easures ANOVA followed by the Least-Squares Means
LSMeans) Tukey Honestly Signiﬁcantly Different (HSD) test.
ercent changes in hemodynamic parameters at 6 h after
dministration of nicorandil were analyzed using the paired
-test and the Jonckheere trend test. Intergroup compari-
on of percent change in PAWP by baseline characteristics
as performed using one-way ANOVA. The relationships of
ercent changes at 6 h after administration of 0.20mg/kg/h
icorandil between CI and SVI, and CI and TPR were analyzed
sing Pearson’s correlation analysis.
Changes in blood pressure at 15min were analyzed after
ividing all the patients according to increments of 20mmHg
f SBP before nicorandil administration (baseline SBP) using
he paired t-test. There was no statistical difference in dis-
ribution of each dose among the baseline SBP levels, and
t was demonstrated that the peripheral vasodilating effect
f nicorandil with bolus injection lasted for 15min (data are
ot shown). Therefore, all the data were pooled to evalu-
te the inﬂuence of bolus injection on blood pressure for
ubanalysis.
An adverse reaction was deﬁned as an adverse event for
hich a causal relationship with the study drug could not
e ruled out. The number of occurrences and the incidence
ere determined for each adverse reaction. A two-sided sig-
iﬁcance level of 15% was used for the analyses of patient
haracteristics, and a two-sided signiﬁcance level of 5% was
sed for the other analyses. Statistical analyses were per-
ormed using JMP (JMP version 7.0.1, SAS Institute Japan,
okyo, Japan).
esults
atient baseline characteristics
able 1 shows baseline characteristics of the study patients.
f the 99 patients eligible for analysis, 31 were females,
he mean age was 67.1± 11.0 years, and 35 patients had
ew-onset of acute heart failure. The principal underly-
ng diseases were as follows: ischemic heart disease, 40
atients; valvular disease, 22 patients; hypertension, 15
atients; and dilated cardiomyopathy, 18 patients. Inter-
roup differences were observed for gender, body weight,
nd number of patients with valvular disease, but no sig-
iﬁcant difference among the groups was observed for any
f the other characteristics. Before the initiation of nico-
andil administration, all the patients in all three groups had
eceived early treatment for heart failure including oxygen
nhalation therapy, and 81.8% had been treated with drugs.
aseline values for hemodynamic parameters are presented
n Table 2. PAWP and CI values for the entire patient group
ere 25.7± 6.4mmHg and 2.47± 0.94 L/min/m2, respec-
ively. An intergroup difference was observed for RAP, but
ot for any of the other parameters.
hanges in pulmonary artery wedge pressure and
ardiac index over time
he time course of PAWP is plotted in Fig. 2, and the
ercent changes in PAWP at 6 h are shown in Table 3.
hen nicorandil was administered as a 0.2mg/kg/5min
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Figure 1 Distribution of patients.
Table 1 Baseline characteristics of study population.
Bolus (mg/kg/5min) 0.2 Mean± SD/total (%) p Value
Infusion (mg/kg/h) 0.05 0.10 0.20
N 28 37 34 99 (100)
Gender
Female 12 5 14 31 (31.3) 0.013
Body weight (kg)
(Mean± SD) 55.8± 11.4 62.0± 12.2 57.3± 12.0 58.6± 12.1 0.090
Age (y)
(Mean± SD) 67.5± 11.4 65.9± 12.6 68.1± 9.0 67.1± 11.0 0.692
Principal underlying disease
Ischemic heart disease 14 16 10 40 (40.4) 0.234
Valvular disease 3 7 12 22 (22.2) 0.057
Hypertension 4 5 6 15 (15.2) 0.879
Dilated cardiomyopathy 6 9 3 18 (18.2) 0.208
Other diseases 1 0 3 4 (4.0) 0.167
Type of heart failure
New-onset of acute heart failure 8 14 13 35 (35.4) 0.675
Forrester subset
II/IV 14/14 19/18 21/13 54/45 0.577
Previous medications
ACEI/ARB 9 6 9 24 (24.2) 0.310
Calcium antagonists 7 7 5 19 (19.2) 0.591
-Blockers 0 3 1 4 (4.0) 0.239
Nitrates 12 15 12 39 (39.4) 0.819
Human atrial natriuretic peptide 1 1 1 3 (3.0) 0.979
Digitalis 8 11 14 33 (33.3) 0.486
Catecholamines 1 3 2 6 (6.1) 0.749
Other inotropic agents 3 3 1 7 (7.1) 0.470
Diuretics 18 24 19 61 (61.6) 0.697
Concomitant drugs
Absent 2 8 8 18 (18.2) 0.198
Present 26 29 26 81 (81.8)
Baseline SBP (mmHg)
≤100 1 3 4 8 (8.2) 0.885
101—120 6 12 8 25 (25.5)
121—140 7 9 9 25 (25.5)
141—160 9 9 10 28 (28.6)
161< 5 4 3 12 (12.2)
Each value represents the number of patients or mean± SD. ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor
antagonists; SBP, systolic blood pressure. Statistical analyses were performed by ANOVA or the 2 test.
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Table 2 Baseline hemodynamics in patients with acute decompensated heart failure.
Bolus (mg/kg/5min) 0.2 Total p Value
Infusion (mg/kg/h) 0.05 0.10 0.20
N 28 37 34 99
PAWP (mmHg) 27.1± 6.3 25.0± 6.6 25.3± 6.3 25.7± 6.4 0.403
CI (L/min/m2) 2.36± 0.67 2.45± 0.96 2.57± 1.12 2.47± 0.94 0.681
SVI (mL/beat/m2) 27.0± 8.3 28.9± 12.7 29.9± 17.4 28.7± 13.5 0.701
SBP (mmHg) 142± 27 134± 31 131± 22 135± 27 0.297
DBP (mmHg) 82± 13 77± 16 75± 14 77± 15 0.158
TPR (dyn s cm−5) 2141± 681 1803± 618 1894± 916 1928± 755 0.200
HR (beat/min) 91± 18 89± 21 93± 24 91± 21 0.772
RAP (mmHg) 8.26± 3.63 11.03± 5.84 9.97± 5.70 9.90± 5.34 0.122
PRP (mmHgbeat/min) 12944± 3901 12000± 4159 12217± 4239 12341± 4093 0.643
Each value represents the mean± SD. Statistical analyses were perform
index; SVI, stroke volume index; SBP, systolic blood pressure; DBP, dias
rate; RAP, mean right atrial pressure; PRP, pressure rate product.
bolus injection followed by continuous infusion of 0.05,
0.10, or 0.20mg/kg/h, PAWP was signiﬁcantly decreased
compared to the baseline from 15min to 6 h at all three
doses. With 0.20mg/kg/h, the post-bolus PAWP decrease
was maintained until 6 h. At doses of 0.05, 0.10, and
0.20mg/kg/h, the percent change in PAWP at 6 h was
−16.7± 16.0% (p < 0.001), −20.5± 17.4% (p < 0.001), and
−26.5± 21.9% (p < 0.001), respectively, which represented
dose-dependent decreases (p = 0.023).
The course of CI over time is plotted in Fig. 2, and
the percent changes in CI at 6 h are shown in Table 3. CI
was increased immediately after a nicorandil bolus injec-
Figure 2 Effect of nicorandil on pulmonary artery wedge
pressure (PAWP) and cardiac index (CI) in patients with acute
decompensated heart failure. Each point and bar repre-
sents the mean± SE. : 0.2mg/kg/5min + 0.05mg/kg/h,
: 0.2mg/kg/5min + 0.10mg/kg/h, ©: 0.2mg/kg/5min +
0.20mg/kg/h. *p < 0.05 vs pre-value (repeated measures
ANOVA and LSMeans Tukey HSD test).
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led by ANOVA. PAWP, pulmonary artery wedge pressure; CI, cardiac
tolic blood pressure; TPR, total peripheral resistance; HR, heart
ion of 0.2mg/kg/5min in every group, but the change
as maintained thereafter only with 0.20mg/kg/h. At doses
f 0.05, 0.10, and 0.20mg/kg/h, the percent increase
n CI at 6 h was 6.8± 34.6%, 8.3± 20.9% (p = 0.026), and
5.8± 32.1% (p = 0.010), respectively, which represented
ose-dependent increases (p = 0.032).
hanges in other hemodynamic parameters over
ime
he time course of the other hemodynamic parameters
s also plotted in Fig. 3, and the percent changes at 6 h
re given in Table 3. SBP was signiﬁcantly decreased at
5min, and this decrease was maintained for 6 h with
.10mg/kg/h and 0.20mg/kg/h. Mean changes in SBP
ere −5.9± 7.3mmHg and −7.4± 11.0mmHg at 15min
nd 6 h with 0.10mg/kg/h, and −6.3± 12.8mmHg and
11.5± 14.6mmHg at 15min and 6 h with 0.20mg/kg/h,
espectively. There was no clinically excessive decrease in
BP throughout the administration. DBP, TPR and RAP had
igniﬁcant decreases at 15min, and these changes were
aintained for 6 h with 0.10mg/kg/h and 0.20mg/kg/h.
R did not change signiﬁcantly in any group during the
dministration. Pressure rate product (PRP) decreased sig-
iﬁcantly at 6 h with 0.10mg/kg/h and 0.20mg/kg/h. The
ercent changes in SVI, SBP, TPR, and PRP at 6 h were sig-
iﬁcantly dose-dependent as were those of PAWP and CI.
owever, there was no signiﬁcant dose-dependent change
n RAP, since the change reached a plateau at 0.10mg/kg/h
Table 3).
The relationships of percent changes between CI and
VI, and CI and TPR at 6 h with 0.20mg/kg/h of nicorandil
re shown in Fig. 4. Positive signiﬁcant correlation between
I and SVI (R = 0.901, p < 0.001), and negative correlation
etween CI and TRP (R =−0.806, p < 0.001) were observed.hanges in blood pressure at 15min
ig. 5 shows changes in SBP and DBP at 15min in patients
ivided according to increments of 20mmHg in the base-
ine SBP. There was no signiﬁcant decrease in SBP at
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Table 3 Percent change in hemodynamic parameters at 6 h after administration of nicorandil in patients with acute decom-
pensated heart failure.
Bolus (mg/kg/5min) 0.2 p Value
Infusion (mg/kg/h) 0.05 0.10 0.20
PAWP −16.7± 16.0** −20.5± 17.4** −26.5± 21.9** 0.023
CI 6.8± 34.6 8.3± 20.9* 15.8± 32.1* 0.032
SVI 4.9± 31.7 13.1± 25.5** 18.6± 37.3** 0.039
SBP −1.6± 8.1 −5.1± 7.8** −7.9± 10.6** 0.003
DBP −2.3± 11.9 −8.0± 17.5* −8.8± 10.8** 0.053
TPR −1.6± 21.0 −9.9± 19.7** −13.8± 27.5** 0.009
HR 2.0± 11.4 −2.7± 13.3 −1.0± 9.4 0.294
RAP −5.6± 23.6 −13.5± 40.6 −11.6± 45.9 0.089
PRP 0.3± 12.7 −7.8± 14.5** −8.9± 13.6** 0.005
’ obta
1
w
S
p
F
E
0
p
rEach value represents the mean± SD of percent change. ‘‘p value’
* p < 0.05 vs pre-value (paired t-test).
** p < 0.01 vs pre-value (paired t-test).5min when the baseline SBP was 120mmHg or below,
hile a signiﬁcant decrease was detected with baseline
BP values over 120mmHg. The mean change in SBP in
atients with baseline SBP greater than 160mmHg was
−
s
t
b
igure 3 Effect of nicorandil on hemodynamic parameters
ach point and bar represents the mean± SE. : 0.2mg/kg/5
.2mg/kg/5min + 0.20mg/kg/h. *p < 0.05 vs pre-value (repeated me
ressure; HR, heart rate; DBP, diastolic blood pressure; SVI, stroke
ate product; RAP, mean right atrial pressure.ined by Jonckheere analysis. Abbreviations are deﬁned in Table 2.22.7± 20.3mmHg (p = 0.003). In contrast, DBP decreased
igniﬁcantly in patients with baseline SBP below 100mmHg
o over 160mmHg, with the exception of 121—140mmHg
aseline SBP.
in patients with acute decompensated heart failure.
min + 0.05mg/kg/h, : 0.2mg/kg/5min + 0.10mg/kg/h, ©:
asures ANOVA and LSMeans Tukey HSD test). SBP, systolic blood
volume index; TPR, total peripheral resistance; PRP, pressure
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Figure 4 Regression analyses between cardiac index (CI) and
stroke volume index (SVI) (A), and CI and total peripheral resis-
Figure 5 Acute effect of nicorandil on blood pressure accord-
ing to baseline systolic blood pressure (SBP) in patients with
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dtance (TPR) (B) using Pearson’s correlation analysis. Each point
represents the percent change at 6 h with 0.20mg/kg/h of nico-
randil.
Safety
There were 8 adverse reactions, including headache in 5
patients (5.1%) and decreased blood pressure, premature
ventricular contraction, and ventricular tachycardia in one
patient (1.0%) each. None of the adverse reactions was con-
sidered severe. Nicorandil treatment was not discontinued
in any patient because of adverse reactions. No complica-
tions were caused by a Swan-Ganz catheter. No death during
nicorandil administration was reported.
Discussion
Results of the present investigation showed that intravenous
nicorandil given to patients with ADHF as a bolus injection
followed by continuous infusion reduced the preload and
afterload immediately after the initiation of treatment and
rapidly improved and stabilized hemodynamics in a dose-
dependent manner. Nicorandil was also administered safely
in all patients during the study period without any severe
adverse reactions.
Because vasodilators rapidly improve hemodynamics,
they are widely used along with diuretics to treat acute
c
t
t
r
acute decompensated heart failure. Each point and bar repre-
ents the mean± SD. *p < 0.05, **p < 0.01 vs pre-value (paired
-test). DBP, diastolic blood pressure.
eart failure [17]. In the ESC guidelines [2], use of
asodilators to treat ADHF is recommended when pulmonary
ongestion is present and if SBP is greater than 90mmHg.
he ESC guidelines also suggest that early reperfusion treat-
ent may be effective in ADHF in patients with underlying
cute coronary syndrome.
Three dosage groups were included in the present anal-
sis; in those groups, nicorandil was administered as a
.2mg/kg/5min bolus injection followed by continuous
nfusion of 0.05, 0.10, or 0.20mg/kg/h. Signiﬁcant differ-
nces among the three dosage groups were observed for
ender, body weight, and number of patients with valvu-
ar disease. However, differences in response attributable
o gender were not observed (data not shown). Differences
n body weight were inconsequential, since the dosages were
peciﬁed according to body weight. Furthermore, the per-
ent decrease in PAWP in patients with underlying valvular
eart disease did not differ signiﬁcantly from the percent
ecrease in other patients. Accordingly, the inﬂuence of
he differences in baseline characteristics was thought to
e small.
In the current investigation, bolus injection of nicorandil-
nduced rapid improvement in PAWP and CI; with continuous
nfusion, particularly at 0.20mg/kg/h, these changes were
aintained throughout the treatment. As stated earlier,
icorandil monotherapy has been reported to improve
emodynamics in chronic congestive heart failure when
dministered as a single intravenous injection [14] or as
continuous infusion [15,16]. Giles et al. [14] reported
hat single intravenous doses of nicorandil improved hemo-
ynamics immediately after administration. Because rapid
emodynamic improvement in the acute phase is essential
n the treatment of ADHF, loading of nicorandil with bolus
ntravenous administration would be favored in this clinical
etting.
Nicorandil signiﬁcantly increased CI and SVI, and
ecreased TPR, while nicorandil did not change HR. The
hange in CI was signiﬁcantly positively correlated with
hat of SVI, and signiﬁcantly negatively correlated with
hat of TPR. In a canine acute heart failure model, nico-
andil increased stroke volume, which was accompanied by
marked decrease in left ventricular end-systolic volume
2[
i
r
a
c
m
t
r
c
e
i
b
H
u
n
a
a
n
A
s
a
(
n
b
C
n
c
c
f
l
i
o
d
d
p
r
t
e
i
N
w
a
n
a
t
v
T
a
w
s
v
s
i
c
c
a
i
p
d
i
r
m
i
n
p
a
i
S
T
t
m
e
t
t
w
b
o
i
a
s
d
f
i
c
o
a
t
C
I
r
i
p
r
a
r
f
A
T
m
J
L
A
I
s98
18]. Therefore, it is suggested that the nicorandil-induced
ncreases in CI and SVI were mainly associated with afterload
eduction.
Nicorandil has been found to act by two mechanisms,
KATP channel opening action and a nitrate-like action in a
anine heart failure model [19]. KATP channel opening agents
ainly dilate arteries but do not affect veins [19,20], and
heir direct action on cardiac function is weak [6,21]. It is
eported that the KATP channel opening action of nicorandil is
onsidered to be predominant in dilating arteries, since the
ffects of nicorandil in decreasing peripheral resistance and
ncreasing cardiac output were inhibited by the KATP channel
locker glibenclamide in a canine heart failure model [18].
owever, which mechanisms lead to improvement in CI are
nknown in ADHF patients, and further investigations are
eeded to clarify this issue.
Nicorandil improves hemodynamics as a potent bal-
nced vasodilator with combined dilation of both arterial
nd venous systems via both KATP channel opening and
itrate-like actions, thus increasing CI and reducing PAWP.
decrease in PAWP was observed with the lowest infu-
ion rate of nicorandil (0.05mg/kg/h), and RAP decreased
nd reached a plateau with the middle infusion rate
0.10mg/kg/h), suggesting that there is a component of
itrate-like action at lower doses of nicorandil as reported
y Giles et al. [14]. A decrease in TPR and increases in
I and SVI were observed at the higher infusion rate of
icorandil (0.20mg/kg/h). In addition, secondary changes in
ardiac function caused by preload and afterload reduction
ould contribute to the hemodynamic improvement. There-
ore, it is apparent that nicorandil can reduce preload in
ower infusion rates of 0.05—0.10mg/kg/h, but for further
mprovement in the afterload and CI, a higher infusion rate
f 0.20mg/kg/h would be more appropriate.
Nicorandil signiﬁcantly decreased blood pressure imme-
iately with bolus injection. This decrease was maintained
uring the infusion while an excessive decrease in blood
ressure did not occur. Decreased blood pressure was
eported as an adverse reaction in only one patient in
his investigation, and it was not severe. Therefore, we
valuated the effect of nicorandil on blood pressure, divid-
ng the baseline SBP according to increments of 20mmHg.
icorandil did not decrease SBP signiﬁcantly in patients
ith low to normal SBP, while it did decrease SBP remark-
bly in patients with an elevated baseline SBP. In addition,
icorandil also decreased DBP signiﬁcantly in patients over
lmost all the SBP range including lower SBP, suggesting
hat nicorandil predominantly dilates peripheral resistant
essels subsequent to maintaining cardiac output and SBP.
hese results coincide well with the report by Minami et
l. [22] that nicorandil decreased blood pressure in subjects
ith a high baseline blood pressure. Elevated blood pres-
ure in patients with ADHF generated by excessively high
essel tone, which is activated by the sympathetic nervous
ystem and renin—angiotensin—aldosterone system, may be
nvolved in the pathology of ADHF. In such cases, nicorandil
ould lead the relaxation of vascular smooth muscle and
ould decrease blood pressure. To clarify the precise mech-
nism of nicorandil on blood pressure in ADHF, further study
s needed.
Nicorandil decreased PRP signiﬁcantly at 6 h in the
resent investigation, suggesting that decreased myocar-
i
I
i
M
NK. Tanaka et al.
ial oxygen consumption may contribute to improvement
n heart failure. Miura et al. [23] reported that nico-
andil inhibits the release of norepinephrine from ischemic
yocardium, and Giles et al. [14] reported that a single
ntravenous administration of nicorandil improved hemody-
amics without concomitant tachycardia or an increase in
lasma catecholamines. Whether or not nicorandil similarly
ffects release of catecholamines with continuous infusion
n ADHF is a subject for future investigation.
tudy limitations
he present investigation consisted of two separate pro-
ocols. One of the two studies was conducted in an open
anner, and thus the bias of patient selection is not fully
xcluded. Since the studies were conducted to evaluate
he efﬁcacy of nicorandil in any type of ADHF, no limita-
ion for a principal underlying disease or cardiac function
as established in patient enrollment. Therefore, the num-
er of patients was not sufﬁcient to analyze the efﬁcacy
f nicorandil on hemodynamics for each principal underly-
ng disease. The prescription rates of ACE inhibitors/ARBs
nd -blockers were 24.2% and 4.0% respectively since the
tudies were conducted between 1995 and 2000 when these
rugs were not fully established treatments for chronic heart
ailure. It is recommended that future studies be carried out
n a large number of ADHF patients, which would include a
ontrol group, measurement of neurohormones, evaluation
f effects on coronary perfusion and myocardial injury, and
ssessment of outcomes such as mortality and rehospitaliza-
ion.
onclusions
n patients with ADHF, intravenous administration of nico-
andil by bolus injection followed by continuous infusion
mproves PAWP and CI immediately and continuously as a
otent vasodilator with combined preload and afterload
eduction, via the dual mechanism of KATP channel opening
nd nitrate-like actions. These ﬁndings indicate that nico-
andil could be an effective and beneﬁcial new medication
or the treatment of ADHF.
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